<code id='3EEBBA161B'></code><style id='3EEBBA161B'></style>
      • <acronym id='3EEBBA161B'></acronym>
      <center id='3EEBBA161B'><center id='3EEBBA161B'><tfoot id='3EEBBA161B'></tfoot></center><abbr id='3EEBBA161B'><dir id='3EEBBA161B'><tfoot id='3EEBBA161B'></tfoot><noframes id='3EEBBA161B'>
      • <optgroup id='3EEBBA161B'><strike id='3EEBBA161B'><sup id='3EEBBA161B'></sup></strike><code id='3EEBBA161B'></code></optgroup>
        5. <b id='3EEBBA161B'><label id='3EEBBA161B'><select id='3EEBBA161B'><dt id='3EEBBA161B'><span id='3EEBBA161B'></span></dt></select></label></b><u id='3EEBBA161B'></u>
          <i id='3EEBBA161B'><strike id='3EEBBA161B'><tt id='3EEBBA161B'><pre id='3EEBBA161B'></pre></tt></strike></i>
           


   

   

   
   
   
   
   
   
   
   
   
   
   
   
   

   
   
   
   
   
   
   
  
           
  
           
  
           
   
           
    
           
     
           
      
           
       
      
           
      
           
       
           
        
           
         
           
           
          
           
         
           
         
           
           
          
           
         
           
          
        
           
       
           
       
           
        
           
        
           
        
           
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
       
           
       
           
        
           
        
          
          00:00 
        
           
       
           
       
           
      
           
      
           
        
        
        
       
           
        00:00 
         
        00:00 
        LIVE 
       
           
        
       
           
        
           
        
           
        
           
        
           
       
           
       
           
       
           
        
        
        
        
        
        
        
        
        
      
           
       
    
    
      
           
       
           
      
           
     
           
     
           
       
     
           
     
           
      
           
      
           
      
           
      
           
       
           
      
           
      
           
      
           
       
           
       
          
         buffering 
       
           
      
           
      
           
       
           
        
           
        
          
          Replay 
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
        
           
        
           
        
           
       
           
      
           
      
           
      
           
      
           
      
           
       
           
      
           
     
           
     
           
      
           
     
           
     
           
      
           
       
           
        
           
       
           
       
           
        
          
          LIVE 
        
           
        00:00 
         /  
        00:00 
       
           
       
           
        
           
        
           
        
           
         
           
         
           
         
           
         
           
         
           
         
           
        
           
        
           
        
           
       
           
       
           
        
           
        
          
          LIVE 
        
           
       
           
       
           
        
           
        
          
          CC 
        
           
       
           
       
           
        
           
       
           
       
           
       
           
        
           
        
           
         
           
        
           
       
           
       
           
        
           
       
           
      
           
      
           
       
           
        
           
        
           
         
           
         
           
         
           
          
           
          
           
          
           
         
           
        
           
       
           
      
           
      
           
       
           
     
       
           
    
       
           
       
    
  
       
           
   
       
           
       
       
           
      
           
      
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       Opacity : 
        
      
           
     
           
     
           
     
           
      
           
  
     
           
    
           
    
           
    
           
     
          
       Share: 
     
           
      
     
           
      
      Copy 
     
           
      
    
           
    
          
      Close 
      
    
           
    
           
      
    
           
    
           
   
           
  
           
  
           
    
    
    
   
           
   
           
 
    
   
           
   
           
   
           
    
           
     
           
      
           
       
           
        
           
          
          
         
          
          Wikipedia 

          
          
            
          
          

           
           
        
           
       
           
      
           
     
           
    
           
    
           
     
           
      
           
      
           

                       
          Wikipedia  
          
                                   
                 
                                      author：entertainment   
                                        
                                      
                                      -
 
browse：24
                                  
                                    
          
                                    
            
          
 
          Illustration of sound waves coming out of an ear and at the end of these waves we have a figure trying to push back against them and contain them. -- health coverage from STAT
          Advances in gene therapy could eventually "cure" many forms of congenital deafness. The changes have many deaf people worried about the future of their communities.																									Eros Devishi for STAT
          When Yilai Shu was training to be an otolaryngologist in Shanghai, in the mid 2000s, he often met parents with congenitally deaf kids.
          “They always asked me, ‘Do you have any drugs to treat our kids?’ said Shu, who is hearing and a professor at Fudan University in China. “That’s what really inspired me to think about developing a drug.”
          advertisement
          Decades later, Shu is closer than ever to such a drug. In October, he presented extraordinary data at a conference: His team had successfully enabled hearing in four congenitally deaf children using gene therapy. The work is the culmination of decades of genetic research and has spurred companies like Regeneron and Eli Lilly to swoop in and back other groups developing similar treatments.
          The hearing gains are modest and the technology is currently limited to a type of deafness that only affects 1% to 8% of deaf people globally, but some experts suggest that gene therapy could eventually apply to as many as half of all congenitally deaf people. These treatments would have massive implications for the 12,000 kids born with hearing loss in the United States every year.
          “This has been the dream of our field for 30-plus years to come up with a molecular treatment to give people real, natural hearing, that they were originally intended to have,” said Larry Lustig, a hearing otolaryngologist at Columbia University who is leading a Regeneron-backed trial showing promising results using gene therapy to treat deafness. “This is going to be transformative.”
          But this transformative technology faces a problem: not all deaf people want it.
          STAT+ Exclusive Story
          Already have an account? Log in
          STAT+
          This article is exclusive to STAT+ subscribers
          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
          Already have an account? Log in
          Already have an account? Log in
          Monthly
          $39
          Totals $468 per year
          $39/month			Get Started			
          Totals $468 per year
          Starter
          $30
          for 3 months, then $39/month
          $30 for 3 months			Get Started			
          Then $39/month
          Annual
          $399
          Save 15%
          $399/year			Get Started			
          Save 15%
          11+ Users
          Custom
          Savings start at 25%!
          Request A Quote			Request A Quote			
          Savings start at 25%!
          2-10 Users
          $300
          Annually per user
          $300/year			Get Started			
          $300 Annually per user
          View All Plans																															
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
           
 
 
          

                              
          
                                 Previous article：

                                
                                          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
                                
                            
          Next article：  
                                      
                                          Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'
                                                                    
          

      
           
      
           
        
           
                                               
        
           hotspot 
           
                   
      
           
  
  
          
    
          
        
          
            
          
                                                     
                
          focus
          
                            
          
        
          
        
    
          

          

    

      
           
     
           


   
    
           
   
           
  
 

  
           
    
           
           
           
            
            Back To Top 
           
           
           
           

            
           
                                                                    
                 
          hotspot
           
                                      
            
           
          
           
                                                          
             
          knowledge
           
                             
            
           
            
           

                                                         
             
          focus
           
               
              
            
           
            
           
                                                         
             
          hotspot
           
                             
      
           
 
     
           
     
           
      
          
              MattRourke/APWASHINGTON—Aspartame,thepopularartificialsweetenerindietsodasandchewinggums,maypossibly
             
           
      
          
        © 2013-2023.Company name All rights reserved.Site Map 
         WSS-More Templates  
             Guangdong ICP7name